Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ATR
ATR logo

ATR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
116.500
Open
116.500
VWAP
114.93
Vol
345.58K
Mkt Cap
7.37B
Low
112.770
Amount
39.72M
EV/EBITDA(TTM)
10.45
Total Shares
63.82M
EV
8.54B
EV/OCF(TTM)
14.09
P/S(TTM)
1.97
AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets.
Show More

Events Timeline

(ET)
2026-04-30
17:10:00
Aptar CEO Predicts Growth Across Segments in Q2
select
2026-04-30
17:10:00
Aptar Q1 Revenue $982.9M Beats Expectations
select
2026-03-19 (ET)
2026-03-19
17:10:00
AptarGroup Collaborates with ENA Respiratory on INNA 051 Clinical Study
select
2026-03-17 (ET)
2026-03-17
17:10:00
AptarGroup Appoints Gael Touya as New CEO
select
2026-02-05 (ET)
2026-02-05
17:10:00
Aptar Sees FY26 Capital Expenditures of $260M-$280M
select

News

Newsfilter
8.5
05-06Newsfilter
Aptar and Clarins Win 2026 DIELINE Award for Sustainable Design
  • Sustainable Design Innovation: The custom reloadable airless packaging solution developed by Aptar and Clarins reduces material impact by 73%, utilizing 50% less metal, 33% less plastic, and 29% less cardboard, significantly enhancing product sustainability and market competitiveness.
  • Industry Recognition: The Clarins Total Eye Lift packaging solution received the Formes de Luxe Award in 2025 and was awarded First Place in the Sustainable Design category at the 2026 DIELINE Awards, highlighting its excellence in innovation and execution.
  • Technological Advantage: Aptar's patented Gaïa airless technology combines a premium metal outer casing with plastic reloads, preserving luxury aesthetics while significantly reducing material usage, enhancing product circularity and consumer experience.
  • Market Impact: This innovation not only elevates Clarins' market differentiation and brand equity but also demonstrates the compatibility of luxury and sustainability, driving progress in the high-end skincare market.
seekingalpha
9.5
05-01seekingalpha
AptarGroup Q1 2026 Earnings Call Insights
  • Financial Performance Overview: AptarGroup reported an 11% increase in sales with flat core sales, achieving adjusted EBITDA of $189 million and an EBITDA margin of 19.2%, indicating that overall performance met expectations amid anticipated emergency medicine destocking.
  • CEO Transition: Current CEO Stephan Tanda announced his retirement effective September 1, with Gael Touya set to take over, highlighting the company's stability and strategic continuity during leadership changes.
  • Market Demand Dynamics: The Pharma segment continues to see growing demand in key areas such as GLP-1, biologics, and systemic nasal drug delivery, with prescription core sales down 10% but injectables core sales up 20%, reflecting a differentiated market trend.
  • Future Outlook and Investment: Management guided for second quarter adjusted earnings per share between $1.32 and $1.40, while planning capital investments of $260 million to $280 million, demonstrating the company's confidence in future growth and commitment to ongoing investments.
NASDAQ.COM
9.5
04-30NASDAQ.COM
AptarGroup Reports Decline in Q1 Earnings
  • Earnings Decline: AptarGroup's Q1 net income fell to $72.67 million, or $1.12 per share, down from $78.79 million and $1.17 per share last year, indicating profitability challenges for the company.
  • Revenue Growth: Despite the earnings drop, the company reported a 10.8% increase in revenue to $982.86 million compared to $887.30 million last year, demonstrating strong sales performance.
  • Adjusted Earnings: Excluding special items, AptarGroup's adjusted earnings were $77.20 million, or $1.19 per share, indicating stability in core operations despite the overall earnings decline.
  • Future Guidance: The company provided Q2 EPS guidance of $1.32 to $1.40, reflecting management's cautiously optimistic outlook for future performance, which may attract investor interest.
seekingalpha
9.5
04-30seekingalpha
AptarGroup Q1 2026 Earnings Exceed Expectations
  • Earnings Beat: AptarGroup reported a Q1 2026 non-GAAP EPS of $1.19, exceeding expectations by $0.04, indicating strong performance and improved profitability in the market.
  • Significant Revenue Growth: The company achieved revenues of $982.9 million in Q1, reflecting a 10.8% year-over-year increase and surpassing market expectations by $26.96 million, demonstrating sustained growth in sales and market demand.
  • Optimistic Outlook: Aptar anticipates adjusted EPS for Q2 2026 to be in the range of $1.32 to $1.40, reflecting confidence in future performance while assuming an effective tax rate between 22.5% and 24.5%.
  • Exchange Rate Consideration: This earnings guidance is based on an exchange rate of 1.18 Euros to USD, highlighting the company's foreign exchange risk management strategy in its global operations.
Newsfilter
2.0
04-22Newsfilter
Aptar Named One of America's Climate Leaders for Fourth Consecutive Year
  • Recognition as Climate Leader: AptarGroup has been named one of America's Climate Leaders by USA Today for the fourth consecutive year, reflecting the company's long-term commitment to sustainability and climate action, thereby enhancing its market reputation in environmental stewardship.
  • Emission Reduction Achievements: Since its 2019 baseline year, Aptar has achieved significant reductions in Scope 1 and Scope 2 emissions, indicating effective measures in reducing climate impact and further solidifying its leadership position in the industry.
  • Science-Based Targets: Aptar's science-based targets align with the goal of limiting global warming to 1.5°C, aiming for reductions in renewable electricity use and Scope 3 emissions by 2030, showcasing its proactive strategies in addressing climate change.
  • Global Recognition and Engagement: Aptar has been recognized by CDP with an
Globenewswire
7.5
04-08Globenewswire
Aptar Partners with Enable for enFuse® Digital Health Solution
  • Strategic Partnership: Aptar Digital Health has formed a strategic partnership with Enable Injections, becoming the preferred digital health partner for the enFuse® system, aimed at enhancing patient experience and engagement throughout the injection process.
  • Digital Solution Features: The new solution will include features such as treatment data recording, onboarding modules, injection guidance, and symptom tracking, empowering patients and caregivers with greater confidence and control over the treatment process, thereby improving adherence.
  • Flexible Architecture Design: Built on a flexible and scalable architecture, the solution will be deployed alongside the enFuse® system, supporting pharmaceutical partners across the entire drug development lifecycle from clinical trials to commercialization, enhancing the therapeutic value.
  • Data-Driven Decision Making: By capturing adherence data and patient-reported outcomes remotely and providing actionable insights through analytics dashboards, the solution will assist pharmaceutical companies in making more informed decisions in clinical development and market readiness, ultimately improving the patient treatment journey.
Wall Street analysts forecast ATR stock price to rise
4 Analyst Rating
Wall Street analysts forecast ATR stock price to rise
1 Buy
3 Hold
0 Sell
Hold
Current: 0.000
sliders
Low
133.00
Averages
145.33
High
156.00
Current: 0.000
sliders
Low
133.00
Averages
145.33
High
156.00
Wells Fargo
Gabe Hajde
Overweight
maintain
$144 -> $145
AI Analysis
2026-05-04
Reason
Wells Fargo
Gabe Hajde
Price Target
$144 -> $145
AI Analysis
2026-05-04
maintain
Overweight
Reason
Wells Fargo analyst Gabe Hajde raised the firm's price target on AptarGroup to $145 from $144 and keeps an Overweight rating on the shares. While the firm acknowledges the Middle East conflict could drive a temporary slow-down for some of its semi-discretionary beauty and personal care products, Wells argues that an impending Pharma inflection, a best-in-class balance sheet, and favorable shareholder returns support an Overweight rating.
BofA
George Staphos
Neutral
maintain
$147 -> $145
2026-04-06
Reason
BofA
George Staphos
Price Target
$147 -> $145
2026-04-06
maintain
Neutral
Reason
BofA analyst George Staphos lowered the firm's price target on AptarGroup to $145 from $147 and keeps a Neutral rating on the shares as part of the firm's preview for the packaging and paper group.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ATR
Unlock Now

Valuation Metrics

The current forward P/E ratio for Aptargroup Inc (ATR.N) is 14.73, compared to its 5-year average forward P/E of 26.64. For a more detailed relative valuation and DCF analysis to assess Aptargroup Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
26.64
Current PE
14.73
Overvalued PE
29.84
Undervalued PE
23.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
13.03
Current EV/EBITDA
11.11
Overvalued EV/EBITDA
14.19
Undervalued EV/EBITDA
11.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
2.38
Current PS
1.74
Overvalued PS
2.69
Undervalued PS
2.07

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

which stocks are recommended to buy today?
Intellectia · 86 candidates
Market Cap: >= 5.00BAnalyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20, PriceAboveMA200One Week Predict Return: >= 4.0%Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
CPAY logo
CPAY
Corpay Inc
23.58B
AKAM logo
AKAM
Akamai Technologies Inc
16.08B
MLM logo
MLM
Martin Marietta Materials Inc
40.94B
VMC logo
VMC
Vulcan Materials Co
43.29B
EAT logo
EAT
Brinker International Inc
7.01B
PM logo
PM
Philip Morris International Inc
291.89B
best earrings stock for tomorrow
Intellectia · 9 candidates
Market Cap: >= 1000.00MAnalyst Consensus: Strong Buy, Moderate BuyWeekly Average Turnover: >= 1,000,000Pe Ttm: <= 25Earnings Surprise: EpsBeatAnnual Eps Yoy Growth: >= 20.0%
Ticker
Name
Market Cap$
top bottom
TMUS logo
TMUS
T-Mobile US Inc
205.36B
SUI logo
SUI
Sun Communities Inc
15.43B
AVY logo
AVY
Avery Dennison Corp
14.37B
UHS logo
UHS
Universal Health Services Inc
12.73B
FLS logo
FLS
Flowserve Corp
9.85B
ATR logo
ATR
Aptargroup Inc
8.20B

Whales Holding ATR

A
AE Wealth Management, LLC
Holding
ATR
+13.83%
3M Return
H
Howard Capital Management, Inc.
Holding
ATR
+11.07%
3M Return
H
Hemenway & Barnes LLP
Holding
ATR
+9.79%
3M Return
H
Hemenway Trust Company LLC
Holding
ATR
+9.13%
3M Return
W
Williams Jones Wealth Management, LLC
Holding
ATR
+8.75%
3M Return
B
Boston Trust Walden Company
Holding
ATR
+5.38%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Aptargroup Inc (ATR) stock price today?

The current price of ATR is 115.51 USD — it has increased 0.22

What is Aptargroup Inc (ATR)'s business?

AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets.

What is the price predicton of ATR Stock?

Wall Street analysts forecast ATR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATR is145.33 USD with a low forecast of 133.00 USD and a high forecast of 156.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Aptargroup Inc (ATR)'s revenue for the last quarter?

Aptargroup Inc revenue for the last quarter amounts to 982.87M USD, increased 10.77

What is Aptargroup Inc (ATR)'s earnings per share (EPS) for the last quarter?

Aptargroup Inc. EPS for the last quarter amounts to 1.12 USD, decreased -4.27

How many employees does Aptargroup Inc (ATR). have?

Aptargroup Inc (ATR) has 14000 emplpoyees as of May 23 2026.

What is Aptargroup Inc (ATR) market cap?

Today ATR has the market capitalization of 7.37B USD.